Japan Generics Move Slowed By Lack Of Pharmacy Incentives
This article was originally published in PharmAsia News
Executive SummaryJapan's effort to encourage greater use of generic versions of the drugs it covers is being hampered by a resistance by some dispensing pharmacies to promote them. The use of generics instead of higher-priced branded drugs is a centerpiece of the government's effort to lower the national cost of spending on medicines. But critics say that while government changes provided incentives to physicians to prescribe generics, they failed to provide enough economic incentives for pharmacies to follow the policy and substitute generics for brands except when a physician instructs them not to do so. Incentives put into the law fall short of what some experts say is needed to make pharmacies comply. (Click here for more - a subscription may be required
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.